Follow us on Twitter
twitter icon@FreshPatents

Cytokine patents

Bulk PDF Downloads
      

This page is updated frequently with new Cytokine-related patent applications.




 Method for obtaining a cytokine-rich composition and composition obtained by means of this method patent thumbnailMethod for obtaining a cytokine-rich composition and composition obtained by means of this method
The invention relates to a method for preparing serums, said serums comprising cytokines and coagulation factors, and for preparing fibrin gel compositions, wherein the method comprises submitting an isolated biological sample comprising platelets and/or leukocytes to different steps of different gravity force to obtain supernatants with high concentrations of cytokines and coagulation factors. The invention also encompasses serums obtainable by this method, and other derived products comprising them.
Nte-sener Healthcare, S.a.


 Combination treatments and compositions for wound healing patent thumbnailCombination treatments and compositions for wound healing
Viral vegf and viral anti-inflammatory cytokine compositions, methods of treatment using them, and kits containing them for use in the promotion and/or improvement of wound healing and/or tissue repair, and for anti-scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications.. .
Otago Innovation Limited


 Red blood cell membrane-derived microparticles and their use for the treatment of lung disease patent thumbnailRed blood cell membrane-derived microparticles and their use for the treatment of lung disease
Cell-based therapies show considerable potential as an immunomodulatory strategy for a variety of lung diseases, including chronic obstructive pulmonary disease (copd), asthma, bronchiolitis, acute lung injury, lung allograft rejection (acute or chronic), pulmonary fibrosis. Described herein is the development of red blood cell membrane-derived microparticles (rbc mps), which are depleted of hemoglobin (hb) and express phosphatidylserine on their surface, for the treatment of lung disease.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


 Pharmaceutical composition for preventing or treating liver diseases, containing plasmalogen precursor, plasmalogen or plasmalogen analog as effective component patent thumbnailPharmaceutical composition for preventing or treating liver diseases, containing plasmalogen precursor, plasmalogen or plasmalogen analog as effective component
The present invention relates to a pharmaceutical composition for preventing or treating liver diseases, containing a plasmalogen precursor, plasmalogen, or a plasmalogen analog as an effective component. More specifically, a plasmalogen precursor, or plasmalogen or a plasmalogen analog produced by metabolizing the plasmalogen precursor, can prevent or treat liver diseases such as hepatic steatosis, hepatitis, or liver cirrhosis, etc.
University Of Ulsan Foundation For Industry Cooper Ation


 Compositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction patent thumbnailCompositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction
Compositions comprising one or more cytokines and methods for their use in inhibiting and/or alleviating effects of radiation therapy and/or chemotherapy and/or acute radiation syndrome in a subject in need thereof are provided.. .
Trifoilium Aps


 Composition for preventing or treating non-alcoholic liver disease or insulin resistance comprising ginsenoside f2 patent thumbnailComposition for preventing or treating non-alcoholic liver disease or insulin resistance comprising ginsenoside f2
The present invention relates to a pharmaceutical composition, a health functional food, and a feed composition for the prevention, improvement, or treatment of non-alcoholic liver disease or insulin resistance comprising ginsenoside f2. The pharmaceutical composition according to the present invention comprising ginsenoside f2 can inhibit the adipogenesis and lipid accumulation in the liver, improve insulin sensitivity, inhibit the expression of inflammatory cytokines such as tnf-α, il-β, and il-6 in the kupffer cell, inhibit the expression of endocannabinoid synthase, thus capable of effectively preventing or treating non-alcoholic liver disease or insulin resistance..
Intelligent Synthetic Biology Center


 Use of sting agonists to treat hepatitis b virus infection patent thumbnailUse of sting agonists to treat hepatitis b virus infection
The invention includes methods of treating a subject having hepatitis b viral (hbv) infection. In certain embodiments, the method of the invention comprises stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular sting agonists, thus suppressing hbv replication in hepatocytes.
Drexel University


 Methods of diagnosing proliferative disorders patent thumbnailMethods of diagnosing proliferative disorders
The present invention relates to methods of diagnosing and/or prognosing proliferative disorders, especially brain cancers (e.g. Gliomas).
University Of Central Lancashire


 Anti-prlr antibodies and uses thereof patent thumbnailAnti-prlr antibodies and uses thereof
The present invention provides antibodies that bind to prolactin receptor (prlr) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human prlr with high affinity.
Regeneron Pharmaceuticals, Inc.


 Novel 8-oxoprotoberberine derivative or pharmaceutically acceptable salt thereof, preparation method therefor and pharmaceutical composition for preventing or treating diseases associated with activity of nfat5, containing same as active ingredient patent thumbnailNovel 8-oxoprotoberberine derivative or pharmaceutically acceptable salt thereof, preparation method therefor and pharmaceutical composition for preventing or treating diseases associated with activity of nfat5, containing same as active ingredient
The preset invention relates to a novel 8-oxoprotoberberine derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases associated with the activity of nfat5 containing the same as an active ingredient. The novel 8-oxoproteoberberine derivative or the pharmaceutically acceptable salt thereof according to the present invention can be useful in a pharmaceutical composition for preventing or treating diseases associated with the activity of nfat5, particularly rheumatoid arthritis or inflammatory diseases, since it is ascertained that the derivative or a pharmaceutically acceptable salt thereof has remarkably increased oral absorption compared with known protoberberine due to an improvement in the properties thereof, and inhibits the activity of nfat5 and the secretion of inflammatory cytokines and reduces the expression of naft5 in mice with rheumatoid arthritis by directly inhibiting the transcription of nft5..
The Catholic University Of Korea Industry-academic Cooperation Foundation


Methods for therapeutic renal neuromodulation


Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.


Immunoregulatory peptides and methods of use


Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and tnf-α secretion through interaction with toll-like receptors.
13 Therapeutics, Inc.


Systems and methods for detecting infectious diseases


Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (pos) location and may be tested at the pos location for multiple markers for multiple diseases, including upper and lower respiratory diseases.
Theranos, Inc.


Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities


Disclosed herein are il-4 cytokine compositions with enhanced biological activity having increased selectivity for il-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (il-4) muteins.

Tissue protective peptides and uses thereof


The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex.
Araim Pharmaceuticals, Inc.


Combination therapy with anti-cd74 and anti-cd20 antibodies provides enhanced toxicity to b-cell diseases


Disclosed are compositions and methods comprising combinations of anti-cd74 and anti-cd20 antibodies or antigen-binding fragments thereof. The antibody combination may also be used with a therapeutic agent that is attached to antibody or fragment thereof or separately administered.
Ibc Pharmaceuticals, Inc.


Compositions including il-18 and il-22 and their use in anti-viral therapies


The present invention is directed to compositions including the cytokines il-18 and il-22 or biologically active fragments or variants thereof. In some embodiments, the compositions further include a pharmaceutically acceptable carrier.
Georgia State University Research Foundation, Inc.


Adipose derived adult stem cells in hepatic regeneration


The present invention provides a method to derive hepatic stem cells from stem cells derived from non-liver tissue. In one embodiment of the invention, hepatic stem cells are derived from adipose stem cells.
Artecel, Inc.


Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines


This invention provides a method to prevent, control, and/or treat an inflammatory disease or disorder by administering at least one agonist of guanalyte cyclase receptor, or pharmaceutical compositions thereof, either alone or either concurrently or sequentially with another compound or an active agent used to treat the disease or disorder, and/or with an inhibitor of cgmp-dependent phosphodieasterases.. .
Synergy Pharmaceuticals, Inc.


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Bone tissue engineering by ex vivo stem cells ongrowth into three-dimensional trabecular metal


Adult autologous stem cells cultured on a porous, three-dimensional tissue scaffold-implant for bone regeneration by the use of a hyaluronan and/or dexamethasone to accelerate bone healing alone or in combination with recombinant growth factors or transfected osteogenic genes. The scaffold-implant may be machined into a custom-shaped three-dimensional cell culture system for support of cell growth, reservoir for peptides, recombinant growth factors, cytokines and antineoplastic drugs in the presence of a hyaluronan and/or dexamethasone alone or in combination with growth factors or transfected osteogenic genes, to be assembled ex vivo in a tissue incubator for implantation into bone tissue..

Transdiscal administration of specific inhibitors of pro-inflammatory cytokines


The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.. .
Depuy Synthes Products, Inc.


Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor


An hdac6 inhibitor (a compound of formula i) is shown to reduce the pathogenesis associated with the b cell mediated autoimmune disease, systemic lupus erythematosus (sle) administration of a compound of formula i attenuated many of the symptoms characteristic of sle including splenomegaly, abnormal b cell differentiation, an increase in the number double-negative thymic t cells, an increase in the level of auto-antibodies such as anti-dsdna, immune complex-mediated glomerulonephritis and an increase in inflammatory cytokine production. Treatment with a compound of formula i also increased the number of the subject's splenic treg cells while removing circulating auto-antibodies inhibition of hdac6 altered bone marrow b cell differentiation by increasing the percentage of cells in the early-stage developmental fractions of both pro- and pre-b cells.
Virginia Tech Intellectual Properties, Inc.


Medical devices containing rapamycin analogs


A medical device comprises a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature.
Abbott Laboratories


Methods for treating ophthalmic disorders, diseases and injuries


The invention is directed to methods for treating ophthalmic disorders, diseases and injuries. In particular, the invention is directed to treating disorders, diseases and injuries of the cornea and ocular surface.
Noveome Biotherapeutics, Inc.


Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression


Treatment of autoimmune and/or inflammatory diseases associated with overexpression of toll-like receptor 3 (tlr3) as well as toll-like receptor 4 (tlr4) and/or tlr3/tlr4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with tlr3 as well as tlr4 and/or tlr3/tlr4 cellular signaling in association with related pathologies is disclosed.
Ohio University


Plasmonic beads for multiplexed analysis by flow detection systems


Disclosed are methods and assays for detection of low concentration analytes such as proteins in a sample, using beads. Specially coated beads allow for femtomolar sensitivity through strong near-infrared fluorescence enhancement on plasmonic beads having gold nanostructures in a coating.
The Board Of Trustees Of The Leland Stanford Junior University


Icos binding proteins


The present invention relates to an icos binding protein, or antigen binding portion thereof that is an agonist human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.
Glaxosmithkline Intellectual Property Development Limited


Human immune therapies using a cd27 agonist alone or in combination with other immune modulators


Methods of inducing t cell proliferation and expansion in vivo for treating conditions wherein antigen-specific t cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one cd27 agonist, preferably an agonistic cd27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-cd40, ox-40, 4-1bb, or ctla-4 antibody or an agent that depletes regulatory cells, or a cytokine.
University Of Southampton


Embryo implantation


The present invention relates to methods of and compositions comprising cytokines for, improving the success rate of embryo implantation and the success rate of pregnancy rates in females, by providing an immunopermissive uterine environment prior to insemination or implantation of embryos. The methods of the present invention are used to make the uterus more receptive or less hostile to, for example, transferred embryos, sperm or other allografted tissue..
Ostara Biomedical Ltd


Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists


Methods of assessing or monitoring the effect, efficacy, responsiveness to treatment, and/or determining a dose or dosing regimen of therapeutic agents, such as integrin beta7 antagonists, for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of using integrin beta7 subunit-containing receptor occupancy by the integrin beta7 antagonist on colonic lymphocytes as an indicator (“biomarker”) of the effect, efficacy, or responsiveness to treatment, and/or as a means to determine dosing or dosing regimens of therapeutic agents such as beta7 integrin antagonists for the treatment of gastrointestinal inflammatory disorders are provided.
Genentech, Inc.


Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue


The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hghrelin.. .
Ipsen Pharma S.a.s.


Method for treating cognitive dysfunction


The present invention provides compositions and methods for treating cognitive impairment or dysfunction in a subject. In particular, the present invention provides a method for using a composition comprising an angiotensin-(1-7) receptor agonist to treat cognitive dysfunction or impairment that is due to a various clinical conditions including, but not limited to, those associated with increase in inflammation, cytokine production, increases in reactive oxygen species, changes in expression of brain inflammatory related genes and/or in the expression of genes involved in learning and memory within the central nervous system of a subject..
Arizona Board Of Regents For The University Of Arizona


Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof


Provided herein are embodiments relating to therapeutic applications of antibodies that modulate; e.g., inhibit the interaction of tim-3 and lilrb2 antibodies. In some embodiments, the antibodies bind tim-3.
Jounce Therapeutics, Inc.


Scaffolds containing cytokines for tissue engineering


The present disclosure provides biocompatible scaffold that promotes m1 or m2 macrophage phenotypes so as to increase vascularization or healing. Also provided are methods of treating a subject in need with the scaffolds described here..
The Trustees Of Columbia University In The City Of New York


Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma


The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of il-4 in el-4 cells, which are mouse t cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube.
Korea Research Institute Of Bio Science And Biotechnology


Substituted imidazo ring systems and methods


Imidazo ring systems substituted at the 1-position, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.. .
3m Innovative Properties Company


Partial peptide of survivin presented on mhc class ii molecule and use thereof


The object aims to provide: a novel tumor antigen; a novel therapeutic agent useful in a method for treating a malignant neoplasm by utilizing the tumor antigen; and a tumor antigen which can be used as the therapeutic agent. Thus, disclosed are: a novel tumor antigen which has an epitope capable of inducing a th1 cell which is a cd4-positive t cell specific to survivin; and use of the tumor antigen.
Tella, Inc.


Immunogenic compositions and methods for treating neoplasia


The invention provides immunogenic compositions comprising neoplastic cells expressing a cytokine (gm-csf) formulated with at least one tlr agonist and methods of using the composition to induce or enhance an immune response.. .
The Johns Hopkins University


Cell permeable inhibitors of the scaffold protein plenty of sh3 domains (posh) or sh3rfl


Plenty of sii3 (posh) and ink-interacting protein 1 (jip-1) function as a multi-protein scaffold network for tcr-mediated jnk1 activation in cd8+ t-cells. Disruption of the posh/jip-1 complex led to profound defects in the activation of jnk1, as well as deficient activation or induction of the transcription factors c-jun, t-bet and eomesodermin furthermore, disruption of the posh/jip complex in cd8+t-cells resulted in impaired proliferation, decreased cytokine expression and the inability to control tumors.
The Curators Of The University Of Missouri


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Treatment of inflammatory diseases by carbon materials


In some embodiments, the present disclosure pertains to methods of treating an inflammatory disease in a subject by administering a carbon material to the subject. In some embodiments, the carbon material selectively targets t cells in the subject.
Baylor College Of Medicine


Composition for preventing and treating immune diseases containing daurinol compound as active ingredient


The daurinol compound according to the present invention exhibits excellent therapeutic effects on arthritis and inflammatory bowel diseases by having an excellent activity in inhibiting the generation of il-17 and tnf-α, which are inflammatory cytokines causing inflammation, and can alleviate transplant rejection by inhibiting the proliferation of alloreactive t cells and increasing regulatory t cells; therefore, the daurinol compound according to the present invention can be used as a pharmaceutical composition capable of treating and preventing immune diseases. In addition, being a natural substance derived from the mongolian medicinal plant haplophyllum dauricum or haplophyllum cappadocicum, the daurinol compound according to the present invention does not cause cytotoxicity and thus may be used as a composition for a functional health food capable of preventing and remedying immune diseases..
The Catholic University Of Korea Industry-academic Cooperation Foundation


Methods for therapeutic renal neuromodulation


Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.


Methods for bilateral renal neuromodulation


Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.


Humanized mice expressing the pyrin domain only protein 2


A transgenic mouse expressing the human gene for pyrin domain-only protein 2 (pop2). Pop2, when expressed in the transgenic mouse model, broadly dampens inflammatory cytokine production, in part through restricting the activation of both nlrp3 and aim2 inflammasomes.
Albany Medical College


Use of monoclonal antibodies for the treatment of inflammation and bacterial infections


A composition includes monoclonal antibodies directed against a circulating proinflammatory cytokine, the antibodies having a high affinity for the fcγriiia receptor (cd16), in particular the fucose level of all of the antibodies of the composition being less than 60%, and preferably less than 50%, and in particular, the galactosylation level of all of the antibodies of the composition being at least 60%, for the use thereof in the context of the prevention or treatment of the early phases of inflammation. A composition including monoclonal antibodies directed against a circulating bacterial toxin, having an improved affinity for the fcγriiia receptor (cd16) with respect to antibodies directed against the bacterial toxin, produced in the cho cell line, for the use thereof in the context of the prevention or treatment of the early phases of a bacterial infection linked to the release of the toxin is also described..

Suppression of cytokine release and cytokine storm


The present invention includes methods and compositions for ameliorating symptoms or treating one or more adverse reactions triggered by infectious diseases or disease conditions that trigger a widespread release of cytokines in a subject comprising the steps of: identifying the subject in need of amelioration of symptoms or treatment of the infectious diseases or disease conditions that trigger a widespread release of cytokines; and administering one or more pharmaceutical compositions comprising a therapeutically effective amount of a curcumin extract, curcuminoids or synthetic curcumin (s-curcumin) and derivatives thereof, or empty liposomes, dissolved or dispersed in a suitable aqueous or non-aqueous medium sufficient to reduce the level of cytokines in the host.. .

Methods for monopolar renal neuromodulation


Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.

Cd40l collectin fusion proteins


The present invention refers to a fusion protein comprising a tnf-superfamily (tnfsf) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof.

Peptide for suppressing osteoclast differentiation and use thereof


The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (il)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of nf-κb and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-b ligand (rankl)-rank signaling pathway, and suppresses the expression of a rankl or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (trap), cathepsin k, or tnf receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration.

Il-15 and il-15raplha sushi domain based modulokines


The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an immunomodulatory antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and a polypeptide comprising the amino acid sequence of the sushi domain of the il-15rα or derivatives thereof; and uses thereof.. .

Chimeric immunoreceptor useful in treating human cancers


The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of t lymphocytes, direct t cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific.

Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1


The present invention relates to the combination therapy of specific tumor-targeted il-2 variant immunocytokines with specific antibodies which bind human pd-l1.. .

Methods for identifying autoimmune arthritis and for screening for inhibitor of activation of autoimmune arthritogenic t cells


Provided are a method for identifying the presence or likelihood of autoimmune arthritis, the method comprising detecting (1) an anti-ribosomal protein l23a antibody or (2) ribosomal protein l23a-reactive cd4+ t cells in a sample derived from a subject; and a method for screening for a substance that inhibits the activation of autoimmune arthritogenic t cells, the method comprising the steps of bringing a test substance into contact with ribosomal protein l23a-reactive t cells, bringing the t cells into contact with ribosomal protein l23a or a fragment thereof, measuring the level of a proinflammatory cytokine secreted from the t cells, and analyzing the test substance-dependent change in the secretion level of the proinflammatory cytokine.. .
Kyoto University


Targeting of cytokine antagonists


The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling.
Centre Hospitalier Regional Universitaire De Montpellier


Targeted modified tnf family members


The present invention relates to a modified cytokine of the tnf superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the tnf superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells.
Centre Hospitalier Regional Universitaire De Montpellier


Targeted modified il-1 family members


The present disclosure relates to a modified interleukin-1 (il-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the il-1 family member cytokine is a mutant, more preferably it is a mutant il-1 with low affinity to the il-1 receptor, wherein said mutant il-1 is specifically delivered to target cells.
Centre Hospitalier Regional Universitaire De Montpellier


Use of a cd6 binding partner and method based thereon


The present disclosure relates to methods for treatment and prevention of disease conditions mediated by t-helper 17 (th17) and/or t-helper 1 (th1) t lymphocytes (t cells). In particular, the present disclosure relates to use of anti-cd6 antibody for treatment of disease conditions mediated by auto-reactive th17 and th1 t lymphocytes.
Center Of Molecular Immunology


Vaccines using high-dose cytokines


The present invention relates to the field of cancer immunotherapy. In particular, vaccines are administered in conjunction with high doses of cytokines to enhance an anti-tumor immune response..
Sunnybrook And Women's College Health Sciences Center


Antibody and cytokine biomarker profiling for determination of patient responsiveness


Compositions and methods are provided for prognostic classification of autoimmune disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of circulating blood levels of serum autoantibodies and/or cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness.
The Board Of Trustees Of The Leland Stanford Junior University


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Receptors for b7-h4


Isolated cell surface receptors for b7-h4 have been identified based on function. B7-h4 receptor activation by b7-h4 on the dendritic cell, t follicular helper cell and germinal center b cell membrane stimulates inhibitory signaling in those leukocytes.
Amplimmune, Inc.


Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems


Psa is delivered to the host by outer membrane vesicles (omvs), secretion structures that target bacterial molecules to host cells. Purified omvs direct the in vitro differentiation of functional tregs with potent suppressive activity in a psa dependent manner.
California Institute Of Technology


Targeting type i nkt cells to control inflammation


Embodiments are directed to methods and compositions for modulating cytokine responses in subject infected by a pathogen.. .
The Board Of Regents Of The University Of Texas System


Production and therapeutic uses of th1-like regulatory t cells


A unique cd4+cd25+ regulatory t cell population develops from naive cd4+cd25− t cells during a th1 polarized immune response (called th1-tr cells). These th1-tr cells can be generated by contacting naïve t cells with mature cd8α+ dendritic cells (dcs) that have been exposed to a th1 polarizing adjuvant and, in some cases, an antigen of interest.
The Board Of Trustees Of The Leland Stanford Junior University


Biomarker for psychiatric and neurological disorders


The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free κ immunoglobulin chains and free λ immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders.
Resvo Inc.


Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same


Provided are isolated nucleic acid molecules encoding chimeric antigen receptors (cars) that bind to tumor antigens. Also provided are isolated polypeptides and cars encoded by the isolated nucleic acid molecules, vectors that include the isolated nucleic acid molecules, cells that include the isolated nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered t cells in a subject, expanding a population of genetically engineered t cells in a subject, modulating the amount of cytokine secreted by a t cell, reducing the amount of activation-induced calcium influx into a t cell, providing an anti-tumor immunity to a subject, treating a mammal having a muc1-associated disease or disorder, stimulating a t cell-mediated immune response to a target cell population or tissue in a subject, and imaging a muc1-associated tumor..
The University Of North Carolina At Charlotte


Immunoprotective primary mesenchymal stem cells and methods


Immunoprotective primary mesenchymal stems cells (ip-msc) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The ip-msc express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (scfv), fab or f(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., il-2, il-4, il-6, il-7, il-9, and il-12), an interferon (e.g., ifnα, ifnβ, or ifnω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides..
The Administrators Of The Tulane Educational Fund


Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer


The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (at-car) system which provides t cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αfitc-car-expressing t cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive fitc-labeled antibodies.
University Of Maryland, Baltimore




Cytokine topics:
  • Antibodies
  • Inflammation
  • Specificity
  • Immunotherapy
  • Major Histocompatibility Complex
  • Compatibility
  • Combination Therapy
  • Histocompatibility
  • Immune Response
  • Monoclonal Antibody
  • Stimulator
  • Therapeutics
  • Immunostimulator
  • Monoclonal
  • Proinflammatory


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.9001

    4741

    1 - 1 - 107